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The concept of a possible role of normal immune responses as a surveillance 
mechanism against malignant cell growth (1, 2) is based on evidence that most 
tumor cells are antigenic in the host of their origin (3-6). Unlike transplantable 
histoincompatible tumors, syngeneic tumors impose rather strict experimental 
difficulties as they evoke a  type of immune response that is often marginal in 
activity and thus is usually measurable only in vivo. However, evidence is ac- 
cumulating  that  immunity  against  syngeneic  tumors  is  a  cell-mediated  im- 
mune response  (7-9)  and  that  the cell-mediated immune response is directed 
exclusively  against  tumor-associated  transplantation  antigens  (TATA)  ~ not 
present on the (original) normal cells. 
Cell-mediated immune responses induced in dissociated lymphoid cell cultures 
against TATA would  facilitate a  deeper understanding  of the  cellular mech- 
anisms underlying tumor immunity in syngeneic hosts. We have therefore at- 
tempted to immunize dispersed mouse lymphocytes in vitro against syngeneic 
antigenic plasma cell tumors (PCT). The purpose of this study was (a) to define 
the parameters of in vitro immunization of mouse lymphoid cells against plasma 
cell tumor TATA, (b) to test for specificity of the cytotoxic response obtained, 
and  (c)  to  compare  quantitatively  syngeneic  tumor  immunity  to  PCT  with 
allograft immunity. The  results suggest that  it is possible to  activate mouse 
lymphocytes against TATA in vitro. A preliminary report has been given else- 
where (10). 
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Materials  and Methods 
Mice.--Highly inbred CBA/H/Wehi (tI-2h),  BALB/c (H-2 d) NZB  (tl-2d),  and  C57BL/6 
([1-2  b) mice were used throughout. 
Preparation o[Cortisone-Resistant Thymocytes.--Female  CBA, BALB/c, or NZB mice 35-4)0 
days old were injected intraperitoneally with 1.5  mg of cortisone acetate suspended in phos- 
phate-buffered saline. 24 h  later,  the thymocytes were removed under sterile conditions. The 
corticosteroid injection resulted in a 75-85% depletion of thymus lymphocytes. 
Cell Suspensions.--Mice  were killed  by cervical dislocation. The spleen and  thymus were 
excised under aseptic conditions, minced, and strained through an g0-gauge stainless sieve into 
cold culture medium. To remove cell clumps, the cell suspensions were placed in a conical tube 
over 1 ml of fetal calf serum (FCS, Commonwealth Serum Laboratories, Parkville, Australia). 
The supernatant fraction, a  single cell suspension, was then taken; and its viability was de- 
termined by the dye exclusion method (11). 
Culture Medlum.-Eagle's  minimal medium with nonessential amino acids  (Grand Island 
Biological Co., Grand Island, N. Y., catalog, no. F-15) was used. This was supplemented with 
I00  U/ml of penicillin G,  100  #g/ml of streptomycin, and 5~c  FCS  and was  buffered with 
sodium bicarbonate. 
Culture System.--The culture system used is a  modification (12)  of that first described by 
Marbrook  (13)  and Diener and Armstrong (14)  and has been used for the induction of in vitro 
allograft responses (12, 15).  It consists basically of a glass tube (diameter 2.1 cm) sealed off at 
the bottom by a  dialysis membrane and suspended from the stopper of an Erlenmeyer flask 
filled with about 50 ml of culture medium. 60 X  10 ~ responder lymphocytes were cultured to- 
gether with 2  )<  10 ~ allogeneic or syngeneic irradiated plasma tumor cells in a volume of 3 ml 
of culture medium in the inside of the glass tube. The cultures were incubated in 10% CO2 in 
air at 37°C. 
Cell-Mediated Cyletoxicity Assay.--The  :~lCr-release  assay used was a  modification of that 
described by Brunner et al.  (16)  and was performed as described previously in detail (12, 15). 
Labeling of target cells:  Usually 3-4 )<  10 ~ tumor cells were labeled with 100 #Ci of chro- 
mate ~lCr (CEA, Gif-sur-Yvette, France) in a final volume of 1 ml of fortified Eagle's medium 
(FEM, Grand Island Biological Co.) for 20 rain at 37°C. The ceils were washed twice through 
FCS and adjusted to a concentration of 10 '~ cells/100 #l. 
Assay:  At  termination of the culture,  the cells from  triplicate cultures were harvested, 
pooled, and washed twice. The viability of the cultured cells was determined by eosin exclu- 
sion. In the experiments in which the cytotoxic activity generated was quantitatively titrated, 
the cells were adjusted to 5  X  10 ~ viable transformed lymphocyles/ml. A dilution of 1:6 and 
1:36 was performed, and the ceils were assayed for cytotoxic activity against a constant num- 
ber of ~lCr-labeied target cells. Thus 1 ml each of the respective cell dilutions was pipetted to 
35 X  10 mm Petri dishes (Falcon Plastics, Inc., Los Angeles, Calif.), and 50bd of the target cells 
(5  X  104 cells)  were added,  resulting in  ratios of  I00,  16.6,  and  2.7  cytotoxic lymphocytes 
(CL)  to one target cell. Each assay was performed in triplicate. The dishes were [)laced in an 
airtight box, gassed with  10%  CO.~,  and rocked on a  platform for either 4  or 6 h. The cells 
were then harvested and transferred into plastic tubes; a drop of 5% sheep red cell (SRC) sus- 
pension was added, the solution was centrifuged, and  the supernatant was separated from the 
pellet. The radioactivities of the supernatant  and  the pellet were determined in a  Packard 
autogamma scintillation counter (Packard  Instrument  Co., Inc., Downers Grove, Ill.),  and 
the results were expressed as  percent of maximal ~Cr release as determined  by freezing and 
thawing 5  X  104 labeled target cells four times. 
"One Way" Mixed Culture.--The mitotic response of mouse lymphocytes against allogeneic 
or syngeneic irradiated  plasma cell  tumors was  determined at  a  ratio  of responder cells  to 
stimulator cells of 30:1.  The culture system used was that of Diener and Armstrong (14), as 
described in detail elsewhere (12). Responder cells (15  X  10 ~) were cultured with 0.5  X  10 ~ ir- HERMANN WAGNER AND  MARTIN RIJLLINGItOFF 
radiated tumor cells, thus keeping the cell density per surface area constant to the system in 
which cytotoxic activity was generated. At termination  of the culture, the cells were pulsed with 
[3H]thymidine (Radiochemical  Centre, Amersham, England) for 7 h at a final concentration of 
0.7/zCi/ml, and the acid precipitable radioactivity was determined according to the method of 
Wilson (17), as described  in detail previously (12). The stimulation index (SI)  compares the 
ratio of [aH]thymidine incorporation of the combination responder cells plus stimulator cells 
with that of the controls (incorporation of responder cells alone and stimulator cells alone). 
Lymphoid Tumor Cells.--Tumor cell lines HPC 108, HPC 6, and Wehi 22 were generously 
provided by Drs. N. L. Warner and A. W. Harris (The Walter and Eliza Hall Institute). Tu- 
mor cell lines EL4 (18) and P815  (19) were originally obtained from Drs.  Brunner and Cerot- 
tini, Lausanne, Switzerland.  All tumor lines were kept in  continuous stationary suspension 
cultures by Dr. A. W. Harris. 
HPC 108 is a mineral-oil-induced  plasma cell tumor, induced in a BALB/c <-->  C57BL 
allophenic mouse and shown by transplantation to be of BALB/c origin (H-2d).  2 The results 
were confirmed by the demonstration that CBA cortisone-resistant thymocytes (H-gk), activa- 
ted in vitro (15) against C57BL (H-2  b) transplantation antigens, were efficient in lysing EL4 
(11-2  b) target cells, but did not lyse HPC 108 target cells. However, when CBA cortisone-resis- 
tant thymocytes were  activated against BALB/c (H-2  d) transplantation antigens, HPC 108 
target cells were effectively lysed (Table I). HPC 6 is a mineral-oil-induced  plasma cell  tumor 
originated in a NZB (H-2  a) mouse. 3 Wehi 22 is a radiation-induced  thymic lymphoma induced 
in a BALB/c (H-2  d) mouse. ~ 
X-Irradiation.--Plasma  cell tumors were irradiated with 4,000 tad  in a  Philips (RT 250) 
X-ray machine (Philips Electronic Instruments, Mount Vernon, N. Y.).  Details of  the irra- 
diation technique for cells have been given by Miller and Sprent (20). 
Mitomycin C Treatment.--Spleen cells were  treated  with mitomycin C  (Sigma  Chemical 
Co.,  St. Louis, Mo.)  at a final concentration of 35 /zg/ml for  30 rain at  37°C and washed 
twice before being used as cell-bound alloantigen. 
RESULTS 
Cytotoxic Allograft Responses Against Myeloma Tumor Cells.--A first series of 
experiments was designed to titrate that cell concentration of irradiated  (4,000 
rad)  allogeneic myeloma tumor cells per 60  X  106 responder cells that  elicited 
optimal cytotoxic activity under the culture conditions used.  Previous experi- 
ments had shown that with the use of allogeneic spleen cells as the source of cell- 
bound alloantigen, peak  cytotoxic activity was obtained after a  6-day culture 
(12,  15).  Thus  60  X  106  CBA  cortisone-resistant  thymocytes  (H-2 k)  were 
cultured together with a  graded  number of irradiated  HPC  108  (H-2  d)  tumor 
cells  (or  irradiated  HPC  6  [H-2  d]  tumor cells).  After  6  days,  cells from  three 
cultures  per  group  were  pooled  and  assayed  for  cytotoxicity  against  the  im- 
munizing tumor cells in a  ~Cr-release assay. As illustrated in Fig. 1, the optimal 
cytotoxic  allograft  response  was  obtained  at  a  ratio  of  responder  cells  to  ir- 
radiated stimulator cells of about 30:1. 
The specificity of cell-mediated cytotoxicity for sensitizing H-2  d alloantigens 
was  established  by  demonstrating  that  CBA  cortisone-resistant  thymocytes 
(11-2 k) activated in vitro against H-2  d PCT were cytotoxic against H-2  ~ tumor 
2 Harris, A. W., M. C. Holmes, and N. L. Warner. Manuscript in preparation. 
3 Warner, N. L. Manuscript in preparation. 4  TUMOR  IMMUNITY  IN  VITRO 
cells of various origin, but were not effective in destroying H-2  b tumor target 
cells (Table II). However, cytotoxic lymphocytes activated against H-2  b tumor 
cells  effectively tysed  H-2  b  target  cells yet  were  not  cytotoxic against  H-2  d 
target cells. 
TABLE  I 
In  Vitro  Characterization  of the It-2 Phenotype of IIPC 108 Plasma  Tumor  Cells 
CBA cortisone-resistant thymocytes (H-2  k) 
activated in vitro against 
Specific lysis of target cells* 
EL4 (H-2  b)  P815 (tt-2  d)  HPC 108 (H-2  d) 
%  %  % 
//_2  b 
(C57BL spleen cells)  71  4-  1.9  19  4-  2.3  6  4-  3.2 
H_2  d 
(BALB/c spleen cells)  8  4-  1.9  84  =t=  1.4  80  ±  2.9 
* The  51Cr  test was performed at a  ratio  of CL  to  target cells of 50:1.  CBA  cortisone- 
resistant  thymocytes  (H-2  k)  were cultured  in  vitro  against  mitomycin C-treated  BALB/c 
spleen cells (H-2  d) or mltomycin C-treated C57BL spleen cells (H-2b). After 6  days' culture, 
the  in  vitro  generated  cytotoxic activity  was  assayed  using  three  different tumor  cells  as 
target cells. Percent specific lysis was calculated by subtracting the mean of background lysis 
from total lysis. Background lysis (in the presence of normal CBA thymocytcs) was: EL4  = 
12 4- 1.3%; P815  =  15 4- 0.9%; HPC 108  =  18 4- 2.5%. Assay time was 4 h. 
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FIG.  1.  Dose-response relationship of cytotoxic activity generated against allogeneic plasma 
cell  tumor  cells.  60  X  106  CBA  cortisone-resistant  thymocytes  (H-2  k)  were  cultured 
with  a  graded  number  of  irradiated  HPC  108  (H-2  d)  O--©--O  or  HPC  6  (H-2  a) 
~k--A--A  plasma tumor cells. Cytotoxic activity generated in three cultures per group 
was assayed in a  51Cr-release test, using the immunizing allogeneic plasma cell tumor cells as 
target cells. Background lysis (in the presence of normal thymocytes) was: HPC 108  =  20  4- 
1.8%, HPC 6  =  24 4- 2.9%. Assay time was 4  h. HERMANN  WAGNEP,.  AND  MARTIN  ROLLINGI-IOFF 
A kinetic study of cell-mediated cytotoxicity generated in vitro against cell- 
bound H-2  ~ alloantigens  (irradiated  HPC 108 cells or HPC 6 cells) was carried 
out  (Fig.  2).  Cytotoxic activity was first detected 3  days after culture.  Peak 
activity was constantly  observed at day 5-6,  and dropped quickly thereafter, 
The  kinetics  of  generation  of  cytotoxic  anti-H-2  activity  were  found  to  be 
identical  when  CBA cortisone-resistant  thymocytes and  CBA spleen  cells as 
responder cells were compared. 
Cytotoxic  Activity  Against  Syngeneic  PCT.--Previous  studies  had  demon- 
TABLE  II 
Specificty  of Cytotoxic  Tumor A llograft Responses 
CL activated in vitro against 
Specific lysis of 51Cr-labeled target cells* 
EL4  (H-2  b)  HPC 108 (H-2  d)  HPC 6 (H-2  d) 
%  %  % 
HPC  108  (H-2  d)  6  ±  2.3  82  4-  1.8  73  4-  1.9 
HPC 6  (H-2  d)  19  4-  3.4  70  q-  2.6  76  4-  1.7 
EL4  (H-2  b)  68  4-  2.1  7  -4-  2.3  9  4-  3.6 
* Ratio of CL to target cells of 50: 1. Specific lysis was calculated by subtracting the mean 
of background lysis (in the presence of normal thymocytes) from total lysis obtained.  Back- 
ground lysis was: EL4  =  10 +  2.3%; HPC  108  =  16 4- 1.2%; HPC 6  =  14 4- 3.1%.  Assay 
time was 4  h. 
IOO 
80 
~  6o 
h  40 
2o 
I  ,I  I  I  I  I 
3  4  5  6  7  8 
CULTURE  TIME  ( DAYS  ) 
FIG. 2.  Kinetics of the generation of cytotoxic tumor allograft responses. 60  X  106  CBA 
cortisone-resistant thymocytes were cultured together with either 2 X  106 irradiated HPC 108 
cells O--O--O  or 1.5 X  106 irradiated HPC 6 cells •  •--•.  Cytotoxic activity 
was assayed in a  ~lCr-release test (4-h incubation time) at a ratio of CL to target cells of 50:1. 
The single points represent background lysis (in the presence of normal thymocytes). TUMOR  IMMUNITY  IN  VITRO 
strated that both HPC 108 PCT and HPC 6 PCT elicited in syngeneic animals 
tumor immunity with subsequent capacity of the host to reject the respective 
tumor (21). It was of interest, therefore, to investigate whether tumor immunity 
against these cell lines could be induced in vitro. From previous experience with 
in vitro allograft responses it was known that there is a critical dose-response 
relationship between the cell-bound alloantigen present in the culture and the 
cytotoxic response generated in a constant number of responder cells (22). Thus 
it was important to titrate out as first step in the syngeneic system the number 
of irradiated (4,000 rad) plasma tumor cells that presented an optimal antigenic 
stimulation to 60 X  106 syngeneic spleen cells per culture. As indicated in Table 
III, both tumor lines elicited in the respective syngeneic spleen lymphocytes a 
cytotoxic immune response in vitro. For 60 X  106 BALB/c spleen cells,  a cell 
concentration of 2 X  106 HPC 108 cells yielded the highest cytotoxic immune 
responses (59 % lysis of HPC 108 target cells).  In the case of NZB spleen cells, 
almost  the  same  concentration of the HPC  6  tumor cells was optimal  (38% 
tysis of HPC 6 target cells). 
Proliferative  Response  Against Syngeneic  PCT.--Since a proliferative response 
precedes the generation of specific cytotoxic effector cells in cell-mediated allo- 
graft reactions (12,  23), a  comparison of the mitotic response elicited by syn- 
geneic PCT  to  that  elicited by allogeneic PCT was  performed. The  "mixed 
culture" was set up at the ratio of responder cells to stimulator cells (30:1) that 
produced the highest cytotoxic activity. The results given in Table IV indicate 
that in the "allogeneic mixture" the highest SI was obtained at day 3 (SI >  5), 
whereas in the "syngeneic mixture" the SI obtained was much lower (SI <  2). 
TABLE  III 
Dose-Response  Relationship of Cytotoxic A cti'dty  Generated Against Sy~geneic 
.Plasma  Tumor Cells 
Syngeneic PCT per culture 
Lysis of syngeneic 51Cr-labeled PCT 
HPC 108" target cells  ltPC 6,  + target cells 
×  106  %  % 
0.1  19  4-  2.5  21  4-  1.5 
0.5  27  =t=  3.8  25  4-  3.6 
l  42  -4-  1.9  38  ~  0.6 
2  .59  =k  2.6  36  4-  1.4 
5  31  ~  2.5  25  ±  1.6 
10  18  :t=  0.9  22  4-  1.4 
The cells  harvested per group were assayed for cytotoxicity against the syngenelc tumor 
cells in a  5tCr-release assay.  Assay time was 6 h.  Background lysis  (in presence of  normal 
spleen cells)  of HPC 108 cells  was 18 4-  1.7~/c,; of HPC 6 cells,  16 =t= 0.6%. 
* BALB/e spleen cells  (60 X  106) were cultured  together with graded  numbers of irradi- 
ated syngeneic HPC  108 PCT for 6 days. 
NZB spleen cells  (60  X  106) were cultured  together with graded numbers of  irradiated 
syngeneie HPC 6 PCT for 6 days. HiERMANN  WAGNER  AND  MARTIN  ROLLINGHO~F:F 
TABLE  IV 
Proliferative Response Against Syngeneic and A llogeneic PCT 
Stimulator  [3H]Thymidine uptake 
cells 
Control  SI  SI 
HPC 108 
(H-2 ~) 
HPC 6 
(H-2  a 
Pulsing 
time  Syngeneic combination 
[  cpm 
Day 3  I 23,000 -4-  5,400 
Day 5  39,160 ~  4,900 
Day3  17,700 :k  2,800 
Day 5  35,600 -~  7,400 
cpm 
17,400 
13,600 
12,700 
13,200 
Allogeneic combination 
cpm 
1.9  95,300 ~  16,700 
3.1  33,060 :t:  2,300 
1.4  77,200 ::k: 11,800 
2.7  28,800 :t:  4,300 
Control 
cpm 
17,590 
11,400 
14,300 
13,100 
6.0 
2.9 
5.4 
2.2 
Irradiated HPC 108 stimulator cells  were cultured either together with a]logenelc  responder 
cells (CBA spleen cells, H-2  k) or with syngeneic responder cells (BALB/c spleen, cells, H-2d). 
Irradiated  HPC 6 stimulator cells were cultured either with allogeneic responder cells (CBA 
spleen cells, H-2  k) or with syngeneic spleen cells (NZB spleen cells, H-2a). [3H]Thymidine 
incorporation was determined at day 3 and day 5 of culture after a 7-h labeling period. 
However, it was noted that at day 5 the SI obtained in the "syngeneic mixture" 
was as high as in the "allogeneic mixture" (SI 2-3). 
Kinetics of Induction of  Tumor Immunity In  Vitro.--A  comparison  of  the 
kinetics of the generation of cytotoxic effector cells against syngeneic PCT with 
that  against  allogeneic  PCT was carried out.  In  these  experiments  the  PCT 
HPC  108 was chosen as a  source of stimulator cells.  The results obtained are 
illustrated in Fig. 3. Clearly, cytotoxic allograft responses were generated earlier 
in  time  than  cytotoxic  responses  against  TATA.  For  example,  at  day  3-4 
significant allograft responses were obtained; they reached a peak at day 6. In 
the syngeneic "mixed culture" there was a lack of cytotoxic activity till day 4. 
However on days 5 and 6 an exponential increase in cytotoxic activity occurred, 
reaching a peak at day 7. Thus there appeared to be a  separation in time be- 
tween the generation of allograft immunity and tumor immunity in vitro. 
Responsiveness  of  Cortisone-Resistant  Thymocytes  Against  TA TA.--Tumor 
immunity is thought to be a cell-mediated immune response and as such to be 
thymus dependent. As routine spleen cells are a mixture of both bone marrow- 
derived  (B)  lymphocytes and thymus-derived (T) lymphocytes, it was impor- 
tant to establish whether T lymphocytes alone could mount a cytotoxic immune 
response against TATA in vitro. Since cortisone-resistant thymocytes were effi- 
cient in cytotoxic in vitro allograft responses (15), the capacity of cortisone-resis- 
tant BALB/c thymocytes to mount a tumor response in vitro against syngeneic 
HPC 108 PCT was investigated. As shown in Fig. 4, cortisone-resistant thymo- 
cytes  alone  generated  antitumor  cytotoxic  activity.  Specific  51Cr release  in- 
creased with increasing ratios of CL to target cells over a range of 2:1 to 100:1. 
Specificity of the Cytotoxic Antitumor Response.--The  specificity of the cyto- 
toxic response against syngeneic tumor cells was investigated.  BALB/c corti- TUMOR  IMMUNITY  IN  VITRO 
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Fro. 3.  Comparison of the kinetics of in vitro generation of eytotoxicity against allogeneic 
and syngeneic PCT. 60 X  106 CBA spleen cells (H-2  k) were cultured together with 2 X  106 
irradiated  HPC  108  PCT  (H-2  a)  ©  O--©  O.  60  X  106  BALB/c spleen cells 
(H-2  d)  were cultured  together  Mth  2  X  106  irradiated  syngeneic HPC  108  (H-2  d)  PCT 
•  •----•.  The cytotoxic activity generated was quantitated  each day at a ratio of CL 
to target cells of 50:1 in a aCr-release assay using the immunizing PCT as target cells. Assay 
time was 6 h. The single points represent  background  lysis. 
sone-resistant  thymocytes were  activated  against  HPC  108  tumor  cells,  and 
the effector cells were assayed for cytotoxic activity against a variety of tumor 
cells of identical H-2 phenotype and against allogeneic EL4 (11-2  b) target ceils 
(Table V). BALB/c-derived cytotoxic lymphocytes activated against HPC 108 
tumor ceils were found to be specifically cytotoxic against HPC 108 target cells. 
However,  in  all  experiments  a  small  but  significant  background  activity was 
noted  against  the  other  tumor cells  tested.  This  unspecific  cytotoxic activity 
was also apparent when responder cells were cultured in the presence of autol- 
ogous irradiated spleen cells. Similar results were obtained when NZB cortisone- 
resistant  thymocytes activated against the syngeneic PCT HPC 6 were tested 
for specificity  (Table V).  In the case of HPC 6  cells,  the background activity 
was even more pronounced. 
Comparison  of Cytotoxic Responses Obtained Against Allogeneic PCT to That 
Against Syngeneic  PCT.--The  cytotoxic  immune  response  obtained  in  vitro 
against histoincompatible  PCT was compared with  that obtained against syn- 
geneic PCT.  Once, CBA cortisone-resistant  thymocytes (H-2  k)  were activated 
against  the  allogeneic  PCT  HPC  108.  To  the  other,  the  same  number  of 
BALB/c  cortisone-resistant  thymocytes  (H-2  d)  were  activated  against  the 
syngeneic PCT HPC 108. After 7 days' culture, the cytotoxic activity generated I-[ERMANN WAGNER  AND  MARTIN  R/JLLINGHOFF  9 
was assayed in vitro under identical conditions using 51Cr-labeled HPC  108 cells 
as  target cells. The  results given in Fig.  5  illustrate that  the magnitude  of the 
cytotoxic immune  responses generated against HPC  108 target cells was about 
30-fold higher when the antigenic difference between responder cells and sfimu- 
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FIG. 4.  Capacity of cortisone-resistant thymocytes to mount cytotoxic immune responses 
against syngeneic PCT. 60  X  106 BALB/c cortisone-resistant thymocytes were cultured to- 
gether with 2 X  106 irradiated syngeneic HPC 108 tumor cells for 7 days. Cells were harvested, 
washed, and assayed for cytotoxic activity at various ratios of CL to target cells against 51Cr- 
labeled HPC  108 cells. Assay time was 6 h. 
TABLE  V 
Specificity of the Cytotoxic Response Against Syngeneic PCT 
Target cells 
Specific lysis of 51Cr-labeled target cells* 
BALB/c cortisone-resistant thymocytes  NZB cortisone-resistant thymocytes 
activated against syngeneic  activated against syngenelc 
HPC 108 PCT  Spleen cells  HPC 6 PCT  Spleen cells 
%  %  %  % 
HPC  108  (H-2  a)  51  4-  1.4  12  :E  1.8  18  4-  1.2  14  ±  1.3 
HPC 6  (H-2  a)  7  4-  2.3  9  4-  2.6  39  :i:  2.4  I1  4-  2.7 
P815  (H-2  d)  11  -4-  1.9  13  4-  0.8  20  :E  0.4  15  4-  2.1 
EL4  (H-2  b)  6  4-  1.7  5  4-  1.3  10  :E  2.2  9  4-  1.1 
* Ratio of CL to target cells of 50:1. Specific lysis was calculated by subtracting the mean 
of background lysis (in the presence of normal thymocytes) from total lysis obtained. Back- 
ground lysis was: HPC  108  =  16 4-  1.3%; HPC 6  =  13 +  0.6~o; P815  =  17  +  0.6%; EL4 
11  +  2.0%. Assay time was 6 h. 10  TUMOR  IMMUNITY  IN  VITRO 
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FIC.. 5.  Comparison of the cytotoxic activity  generated against allogeneic and  syngeneic 
PCT. 60 X  106 CBA cortisone-resistant thymocytes (H-2 ~) were cultured together with 2 X 
106 irradiated allogeneic HPC 108 cells (H-2  d) O  O----O. The same number of BALB/c 
cortisone-resistant thymocytes  (H-2  ~) were cultured  together with 2 X  106 irradiated  syn- 
geneic HPC 108 cells/x---~--2x. After 7 days' culture, the CBA-derived cells were harvested 
and washed, and a dilution was performed, resulting in a ratio of CL to target cells of 100: I, 
16.6: 1, and 2.8:1. The same number of cultures derived from BALB/c cells were harvested, 
pooled, and adjusted to the same volume as the CBA-derived cells and were similarly diluted 
in order to correlate the magnitude of the cytotoxic response against syngeneic PCT with that 
against allogeneic PCT. The assay time of the  51Cr test was 6 h. The ratio of CL to target 
cells necessary to obtain 50% of lysis was compared. The single points represent background 
lysis of HPC  108 target cells. 
lator  cells included transplantation antigens of  the  major histocompatibility 
locus. 
DISCUSSION 
The  data  presented  in this  report  support  three  broad  conclusions. First, 
tumor immunity  can be generated in vitro against syngeneic PCT and measured 
quantitatively in a  51Cr-release  assay. Second, there appear to be quantitative 
differences between in vitro cytotoxic responses directed against normal trans- 
plantation  antigens and  cytotoxic  antitumor responses.  Third,  whereas  the 
specificity in cytotoxic  allograft  reactions is  directed  against phenotypically 
expressed  transplantation antigens, the  specificity of cell-mediated antitumor 
responses appears to be restricted to antigens present only on the immunizing HERMANN  WAGNER  AND  MARTIN  ROLLINGHOFF  11 
syngeneic  PCT.  Such  antigens  seem  not  to  be  related  to  the  major  histo- 
compatibility complex. 
Several considerations led to the assumption that the use of murine plasma 
cell tumors may result in a suitable in vitro model for induction of syngeneic 
tumor immunity. It has previously been shown that both HPC 108 and HPC 6 
PCT were antigenic in vivo, that is, they induced immunity in syngeneic hosts 
that could be transferred by spleen cells  (21). In addition, both tumor lines 
were found to be suitable target cells in ~lCr-release assays, i.e., they were easily 
lysed by cytotoxic lymphocytes activated in vivo against the H-2 phenotype of 
the plasma cell tumors  (unpublished results). These results suggested that if 
cytotoxic tumor immunity was generated in vitro against syngeneic HPC  108 
or HPC 6 tumor cells,  it might be possible to detect the cytotoxic effect in a 
short-term ~lCr-release assay. Finally, no evidence had been so far obtained that 
PCT induced a detectable humoral antibody response in syngeneic hosts (21). 
Thus it was reasonable to assume that antitumor activity generated in vitro 
might reflect mainly a cell-mediated immune response. 
The parameters of in vitro tumor allograft responses against HPC  108 and 
HPC 6 were established. The kinetics of induction of cytotoxic responses and 
the specificity of the cytotoxic effector cells generated were similar to those ob- 
tained with the use of allogeneic spleen cells as stimulator cells in the induction 
phase of in vitro allograft responses (Tables I, II, references 12,  15).  In both 
cases,  the detectable cytotoxic response was  directed against  antigens  of the 
major histocompatibility complex. For example, allogeneic PCT of the  same 
H-2 specificity as the immunizing tumor cells were also found to be effectively 
lysed (Table II). Thus the cytotoxic response generated reflected the charac- 
teristics of transplantation immunity (24) and as such was not due to antigens 
associated only with the PCT tumor cells. 
The concept has been proposed that malignant cells have antigenic qualities 
distinct from those of the cell type from which they are derived (1-6). Since 
there  is  a  lack  of reactivity against  self-transplantation  antigens  in  normal 
organisms,  one would predict that  cocultivation of cortisone-resistant mouse 
thymocytes with  syngeneic plasma  tumor  cells  would  result  in  an  immune 
response directed solely against such antigenic differences between reactive cells 
and tumor cells as are recognized as foreign. Indeed, cytotoxic activity against 
syngeneic murine plasma cell tumors could be generated in vitro, and it appeared 
that  a  critical  ratio  of  spleen  cells  to  irradiated  syngeneic  tumor  cells  was 
necessary to provoke such a response (Table III). The cytotoxic activity gener- 
ated was specifically directed against the antigenic syngeneic tumor cells in the 
sense that syngeneic tumor cells were lysed far more efficiently than other H-2 
phenotypically identical or nonidentical tumor cells. It was noted that although 
specificity for plasma cell TATA could be demonstrated, there was a low but 
significant lysis of other H-2 identical tumor cells (Table V). Furthermore, it 
was found that cortisone-resistant thymocytes cultured in the presence of ir- 12  TUMOR  IMMUNITY  IN  VITRO 
radiated syngeneic spleen cells alone appeared  to acquire a  certain degree of 
unspecific cytotoxic potential against tumor target cells. The magnitude of the 
unspecific  cytotoxicity obtained  when  autologous  spleen  cells  were  used  as 
antigen was  found to be  similar  to  the unspecific lysis noted in  the  case of 
cytotoxic effector cells activated against syngeneic tumor cells. The results ob- 
tained therefore suggested that in vitro activation of cortisone-resistant thymo- 
cytes against  syngeneic plasma  cell tumors  resulted in  two different effector 
stages, one specifically directed against plasma cell TATA, and one resulting in 
unspecific killing of the tumor target cells so far tested. Recent studies of the 
nature of the specific effector cells have provided evidence that the specificity of 
the cytotoxic reaction against TATA is a function of 0-positive lymphocytes, 
a characteristic of T cellsA Whether the unspecific killing is due to cross-reacting 
antigens on the target cells tested or to nonspecific killing of antigenically un- 
related tumor cells, for example by macrophages (25), has to be analyzed. 
Several  techniques,  for  example,  colony  inhibition  (26,  27),  lymphocyte 
transformation  (28),  cytotoxicity  (29),  and  cell  migration  with  peritoneal 
exudate cells and peripheral leukocytes (30-32), have been applied in studying 
cell-mediated immunity against syngeneic tumors. Whereas lymphocyte trans- 
formation has  been used  as  an  in  vitro correlate to  the  antigen  recognition 
phase of lymphocytes reactive against TATA, inhibition of cell migration by 
innnune lymphocytes has been used as a  correlate to the state of tumor im- 
munity,  and  colony inhibition  or cytotoxicity has  been  employed to  detect 
effector cells in tumor immunity.  Since in the present investigation both the 
afferent and  the  efferent limbs  of a  cell-mediated immune  response  against 
plasma  tumor cell TATA were induced in vitro and the effector cell activity 
was measurable in a direct cytotoxicity assay, the cellular mechanism involved 
could be analyzed. 
The results obtained so far have been consistent with the view that tumor 
allograft immunity and tumor immunity against TATA of PCT are of the same 
general quality, that is, a cell-mediated function of T lymphocytes. Similarly to 
in vitro allograft responses (12,  15),  a proliferative response preceded the ap- 
pearance of cytotoxic effector cells against syngeneic PCT, although the mag- 
nitude of cell proliferation was low and cytotoxicity appeared late compared 
with responses against transplantation antigens (Table III, Fig. 3). Corticoster- 
old-resistant thymocytes alone were efficient in mediating both cytotoxic allo- 
graft responses and specific cytotoxic antitumor responses (Fig. 4). Finally, on 
a semilogarithmic scale, a nearly straight-line dose-response curve depicted the 
action of an increasing number of cytotoxic T  lymphocytes on a fixed number 
of target cells over a wide range in both a  tumor allograft system and a  syn- 
geneic  tumor  system  (Fig.  5).  This  finding  suggests  that  the mechanism of 
4 RNlinghoff, M., and H. Wagner. In vitro induction of tumor-specific immunity. II. The 
requirements for T  lymphocytes and the protective potential against tumor growth in vivo. 
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specific in vitro cytotoxicity against syngeneic plasma tumor cells is similar to 
that against allogeneic target cells (15). 
The immunogenicity of PCT TATA was found to be much weaker than that 
of normal transplantation antigens. PCT TATA induced in syngeneic cortisone- 
resistant thymocytes gave about a 30-fold lower cytotoxic response compared 
with that of transplantation antigens. Cytotoxic anti-TATA activity was found 
to  appear  later in  time than cytotoxicity against H-2  alloantigens  (Fig. 4). 
Whether this  difference in  the  induction of cytotoxicity is  due  to  differing 
"antigenic strength" or to a different number of cells responding to the recog- 
nizable "antigenic units" has to be investigated. 
Our studies suggest that HPC 108 and HPC 6 PCT are antigenic in vitro and 
provoke a cytotoxic cell-mediated immune response in syngeneic lymphocytes. 
However, it has to be stressed that the experimental conditions in the PCT 
system used facilitated the detection of cytotoxic immune responses. Besides 
the demonstration that these tumors were immunogenic in vivo (21), the facts 
that they grew in vitro in single cell suspension, were easy to label with alCr- 
chromate,  and were  susceptible to  the lyric effect of cytotoxic lymphocytes 
favored the results obtained. Thus, before general conclusions concerning the 
efficacy of in vitro immunization against TATA are allowed, it is necessary to 
demonstrate that other types of malignant cells are also immunogenic in in vitro 
culture systems. 
SLrMMARY 
Induction of tumor-specific immunity in vitro was accomplished by cocultiva- 
tion of cortisone-resistant murine thymocytes or spleen cells  with irradiated 
syngeneic plasma cell  tumors (PCT). The cytotoxic activity generated could 
be  detected  in  a  short-term  51Cr-release  assay.  Optimal  cytotoxic  activity 
against PCT-associated transplantation antigens (TATA) was generated after 
7 days in culture. Unlike cytotoxic responses to tumor allografts in which the 
cytotoxic activity was directed against allogeneic  transplantation antigens, the 
cytotoxic activity obtained in the syngeneic tumor system was specific to the 
immunizing syngeneic PCT. 
Similar parameters of induction of cytotoxic responses in in vitro tumor allo- 
graft responses and in the syngeneic tumor system suggested that both reactions 
are cell-mediated cytotoxic immune responses. With regard to the magnitude of 
cytotoxic responses obtained, allogeneic transplantation antigens induced about 
a  30-fold  higher  cytotoxic immune  response  than  plasma  cell  TATA.  The 
results are consistent with the concept that in vitro tumor allograft responses 
and in vitro responses against TATA of PCT are similar in quality, but differ in 
the magnitude of the cytotoxic response provoked. 
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